Patients with pancreatic cancer
Conditions
Interventions
None listed
Sponsors
Asahikawa Medical University
Asahikawa-Kosei General Hospital Japanese Red Cross Asahikawa Hospital Asahikawa City Hospital Hokkaido University Hospital Teine Keijinkai Hospital Sapporo Higashi Tokushukai Hospital IMS Sapporo Digestive Disease Center General Hospital Engaru-Kosei General Hospital Nayoro City Hospital Shibetsu City Hospital Shonan Kamakura General Hospital Chibanishi General Hospital Tottori University Hospital Fujita Health University Hospital Yamagata University Faculty of Medicine Osaka
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Japanese patients with pancreatic cancer diagnosed by imaging, blood findings, or histology at Asahikawa Medical University Hospital or the collaborating institution between the date of approval and March 2029. (2) Patients must be at least 18 years old and less than 50 years old at the time of disease onset. (3) Patients or healthy volunteers who have given written consent to participate in this study. (4) Persons between the ages of 18 and 50 years old (regardless of gender) who visit Asahikawa Medical University Hospital or Sapporo Higashi Tokushukai Hospital. (5) Persons who have given written consent to participate in this study.
Exclusion criteria
Exclusion criteria: <Patients with pancreatic cancer> (1) Patients with histologically confirmed endocrine neoplasms (2) Patients with serious underlying diseases or complications that would make it difficult to participate in the study. (3) Patients who no longer meet the above selection criteria after enrollment or who are newly found to be in conflict with the exclusion criteria. (4) Patients who are judged to be inappropriate as research subjects by the physician in charge. <Volunteer> None in particular
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Search for germline mutations using peripheral blood mononuclear cells (all cases). | — |
Secondary
| Measure | Time frame |
|---|---|
| (1) Frequency of detection of multiple lesions including pancreatic cysts by MRI and other imaging modalities (all cases) (2) Functional analysis of somatic mutations and drug responsiveness using primary cells in tumor tissues (in surgical cases where fresh tumor tissues can be secured prior to fixation) | — |
Countries
Japan,North America
Contacts
Public ContactYusuke Mizukami
Asahikawa Medical University Division of Gastroenterology, Department of Medicine
Outcome results
None listed